Earnings call transcript: Cooper Companies Q3 2025 beats EPS expectations

Cooper Companies (COO) reported robust Q3 2025 results, with EPS of $1.10 surpassing expectations and revenue of $1.06 billion meeting forecasts, leading to a 1.76% after-hours stock gain. The company's performance was driven by strong growth in its MyDay and MiSight product lines, though a faster-than-anticipated internal shift from Clarity to MyDay, particularly in Asia Pacific, created some near-term revenue headwinds. Management remains optimistic, projecting $2 billion in free cash flow over the next three years as CapEx normalizes, and is implementing efficiency initiatives to capitalize on MyDay's strong adoption and navigate market dynamics.

Analysis

Cooper Companies (COO) reported a solid Q3 2025, beating EPS estimates with $1.10 versus a $1.06 forecast, while revenue met expectations at $1.06 billion. The core narrative, however, lies within its largest segment, CooperVision (CVI), which posted organic growth of just 2.4%, below expectations. This slowdown was not due to competitive loss but rather a faster-than-anticipated internal cannibalization, where a surge in demand and fitting activity for the premium MyDay product line suppressed orders for the value-oriented Clarity lens, particularly in the Asia Pacific region. While this dynamic creates a near-term revenue headwind and led to conservative Q4 guidance of 2-4% organic growth, management highlighted strong leading indicators for future acceleration, including a significant increase in MyDay fitting sets and trial lenses. Financially, the company demonstrated strong operational discipline, expanding gross margins by 70 basis points to 67.3% and growing non-GAAP EPS by 15% year-over-year. The most significant forward-looking catalyst is the projection of approximately $2 billion in free cash flow over the next three fiscal years, signaling the end of a major capital expenditure cycle and a pivot toward enhanced cash generation and shareholder returns, evidenced by the $52 million in share repurchases during the quarter.

Key Decisions for Investors

• Investors should look past the near-term CooperVision revenue softness and focus on leading indicators for MyDay, as the successful conversion of trial and fitting activity into sales is the primary catalyst for re-acceleration in fiscal 2026.
• The projection of approximately $2 billion in free cash flow over the next three years marks a significant inflection point; consider the potential for accelerated capital returns through share buybacks and debt paydown, which could enhance shareholder value.
• Given the conservative Q4 guidance, which appears to fully price in the Clarity-to-MyDay transition risk, investors should assess whether the current valuation adequately reflects the company's strong underlying profitability and long-term margin expansion and cash generation profile.